SCHEMBL5281838

SCHEMBL5281838

CN1CCC(C2CCN(C(=O)CCC(=O)O)CC2)CC1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 6/20 0.62
GNAO1 P09471 6/20 0.62
GNAI1 P63096 6/20 0.62
ITGB3 P05106 5/20 0.49
ITGA2B P08514 5/20 0.49
NPC1 O15118 1/20 0.46
EPHX1 P07099 2/20 0.43
EPHX2 P34913 2/20 0.43
F2R P25116 1/20 0.42
ALDH1A1 P00352 1/20 0.40
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242393 0.83 SMN1; SMN2 (0.51) ALDH1A1
SCHEMBL12881322 0.81 ACHE (0.51) GNAI3GNAO1GNAI1NPC1EPHX1
SCHEMBL12881314 0.81 L3MBTL3 (0.48) GNAI3GNAO1GNAI1ALDH1A1
Hydrochloric Acid SCHEMBL27078195 0.81 SMN1; SMN2 (0.50) GNAI3GNAO1GNAI1ALDH1A1
SCHEMBL13801429 0.81 ITGB3 (0.69) GNAI3GNAO1GNAI1ITGB3ITGA2B
SCHEMBL13655796 0.79 GNAI3 (0.58) GNAI3GNAO1GNAI1NPC1ALDH1A1
SCHEMBL12881490 0.79 TSHR (0.59) GNAI3GNAO1GNAI1NPC1ALDH1A1
SCHEMBL6602806 0.78 GNAI3 (0.57) GNAI3GNAO1GNAI1NPC1ALDH1A1
SCHEMBL12881325 0.78 GNAI3 (0.49) GNAI3GNAO1GNAI1ALDH1A1CHRM2
SCHEMBL1207136 0.78 GPR119 (0.56) EPHX1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034444-A1 SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-10 US disclosed
EP-1863791-A1 2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2007-12-12 EP disclosed
WO-2006100026-A1 2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-YL-PIPERIDINES USED AS CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034444-A1 SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS CALCRL, CALCR, CALCA GNAI3 431/4885GNAO1 263/4885GNAI1 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.